Yahoo
    OTC Markets OTCPK USD

    Akeso, Inc. (AKESF)

    10.69 +0.31 (+2.99%)
    At close: November 6 at 4:00:00 PM EST
    Loading Chart for AKESF
    Chart Range Bar
    Interval:
    In partnership with ChartIQ

    Recent News

    Phase II Study of Ivonescimab in the Perioperative Setting for Resectable NSCLC Published in Nature Medicine

    Phase II Study of Ivonescimab in the Perioperative Setting for Resectable NSCLC Published in Nature Medicine
    PR Newswire 3d ago
    Ivonescimab Receives NMPA Priority Review for First-Line Biliary Tract Cancer

    Ivonescimab Receives NMPA Priority Review for First-Line Biliary Tract Cancer
    PR Newswire 4d ago
    The U.S. Stocks Quietly Winning the Chinese Drug Boom

    The U.S. Stocks Quietly Winning the Chinese Drug Boom
    Barrons.com 5d ago
    What Akeso Bears Saw Before The Fall

    What Akeso Bears Saw Before The Fall
    Simply Wall St. 6d ago
    Anthropic’s historic IPO; Akeso’s big clinical showing

    Anthropic’s historic IPO; Akeso’s big clinical showing
    Pharma Voice 9d ago
    Ivonescimab Plus Chemotherapy Demonstrates Overall Survival Superiority Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer in HARMONi-GI1 Study Conducted by Akeso in China

    Ivonescimab Plus Chemotherapy Demonstrates Overall Survival Superiority Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer in HARMONi-GI1 Study Conducted by Akeso in China
    Business Wire 14d ago
    Positive Overall Survival Results from the Phase III HARMONi-GI1 Trial of Ivonescimab Plus Chemotherapy Versus Durvalumab Plus Chemotherapy in First-Line Biliary Tract Cancer Presented at the ESMO 2026 Presidential Symposium

    Positive Overall Survival Results from the Phase III HARMONi-GI1 Trial of Ivonescimab Plus Chemotherapy Versus Durvalumab Plus Chemotherapy in First-Line Biliary Tract Cancer Presented at the ESMO 2026 Presidential Symposium
    PR Newswire 14d ago
    Can Expanding Ivonescimab Development Unlock SMMT's Growth Potential?

    Can Expanding Ivonescimab Development Unlock SMMT's Growth Potential?
    Zacks 18d ago
    Akeso Announces Summit Therapeutics and ECOG-ACRIN Cancer Research Group Enter into Phase II/III Clinical Trial Collaboration to Evaluate Ivonescimab in First-Line Biliary Tract Cancer

    Akeso Announces Summit Therapeutics and ECOG-ACRIN Cancer Research Group Enter into Phase II/III Clinical Trial Collaboration to Evaluate Ivonescimab in First-Line Biliary Tract Cancer
    PR Newswire 18d ago
    Akeso Announces Opening of Global Phase II Study of Ivonescimab in First-Line Clear Cell Renal Cell Carcinoma, Including Combination with Cadonilimab

    Akeso Announces Opening of Global Phase II Study of Ivonescimab in First-Line Clear Cell Renal Cell Carcinoma, Including Combination with Cadonilimab
    PR Newswire 20d ago
    Summit Therapeutics Announces Opening of Global Phase II Study of Ivonescimab-Based Regimens in Advanced Clear Cell Renal Cell Carcinoma

    Summit Therapeutics Announces Opening of Global Phase II Study of Ivonescimab-Based Regimens in Advanced Clear Cell Renal Cell Carcinoma
    Business Wire 21d ago

    Related Tickers

    Mobilize your Website
    View Site in Mobile | Classic
    Share by: